InspireMD, Inc. closed its previously announced offering of (i) 7,342,308 shares of the Company’s common stock, par value $0.0001 per share, and pre-funded…
InspireMD, Inc. (NSPR) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. As previously disclosed, on November 16, 2026, InspireMD, Inc. (the “ Company ”) closed its previously announced offering of (i) 7,342,308 shares of the Company’s common stock, par value $0.0001 per share (the “ Common Stock ”), and pre-funded warrants to
- Instrument
- shares of the Company’s common stock, par value $0.0001 per share
- Gross proceeds
- approximately $34.9 million in net proceeds
- Shares
- 7,342,308 shares
Facts are quoted from the filing text and checked against it.
How this was made
The 30-second read
Why it matters
Completion of the base offering plus full exercise of the underwriter option finalizes the total capital raised and confirms the near-term dilution overhang from the additional shares and warrants.
Market read
Traders can update positioning for dilution risk and financing overhang now that the option exercise and final closing are confirmed in a primary SEC filing.
What to watch
Warrant strike prices and the effective dilution per share are not detailed here; traders may need the prospectus/supplement to assess overhang versus runway benefit.
Background
The company used an effective automatic shelf registration (Form S-3) to issue common stock, pre-funded warrants, and accompanying Series L warrants, with an underwriter option exercisable within 30 days.
Ticker impact
InspireMD closed its shelf offering, selling 7.34M shares plus warrants, and then exercised an underwriter option adding about $5.3M net proceeds.
Likely mild downside or volatility as the market prices the additional dilution from the option exercise, partially offset by the net cash proceeds.
The filing is a primary disclosure of completed equity issuance and warrant terms, but it does not include guidance or a valuation anchor that would drive a large directional repricing by itself.
Market effects
Adds to the broader pattern of small-cap biotech/medtech using shelf offerings and warrant structures for funding.
No direct regional spillover beyond US small-cap risk appetite.
Limited, company-specific capital-raise disclosure with no stated cross-border operational impact.
Counterpoint
If the company’s cash runway is the key constraint, the incremental $5.3M net proceeds could reduce financing risk and support the stock on dips.
Key entities
- issuerInspireMD, Inc.
Subject of the 8-K, closing a shelf offering and the underwriter option on Nov 20, 2026.
- underwriterLake Street Capital Markets, LLC
Representative for the underwriters that exercised the option in full.
- warrant agentSecurities Transfer Corporation
Warrant agent under the warrant agency agreement dated Nov 12, 2026.


